RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer

Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAF(V600E) colorectal cancer (mCRC(BRAF-V600E)). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a disco...

Descripción completa

Detalles Bibliográficos
Autores principales: Elez, Elena, Ros, Javier, Fernández, Jose, Villacampa, Guillermo, Moreno-Cárdenas, Ana Belén, Arenillas, Carlota, Bernatowicz, Kinga, Comas, Raquel, Li, Shanshan, Kodack, David Philip, Fasani, Roberta, Garcia, Ariadna, Gonzalo-Ruiz, Javier, Piris-Gimenez, Alejandro, Nuciforo, Paolo, Kerr, Grainne, Intini, Rossana, Montagna, Aldo, Germani, Marco Maria, Randon, Giovanni, Vivancos, Ana, Smits, Ron, Graus, Diana, Perez-Lopez, Raquel, Cremolini, Chiara, Lonardi, Sara, Pietrantonio, Filippo, Dienstmann, Rodrigo, Tabernero, Josep, Toledo, Rodrigo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556333/
https://www.ncbi.nlm.nih.gov/pubmed/36097219
http://dx.doi.org/10.1038/s41591-022-01976-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556333/
https://www.ncbi.nlm.nih.gov/pubmed/36097219
http://dx.doi.org/10.1038/s41591-022-01976-z

Ejemplares similares